Advanced search
Publication Cover
Aging Health Volume 2, 2006 - Issue 6
Journal homepage
45
Views
0
CrossRef citations to date
0
Altmetric
Review

Treatment Options for Colorectal Cancer in the Elderly

J Feliu1 Medical Oncology Service, La Paz Hospital, Pº de la Castellana, 261-28046, Madrid, Spain Tel.: +3 491 727 7118; Fax: +3 491 727 7118; E-mail: [email protected]
,
J Castro1 Medical Oncology Service, La Paz Hospital, Pº de la Castellana, 261-28046, Madrid, Spain Tel.: +3 491 727 7118; Fax: +3 491 727 7118; E-mail: [email protected]
,
C Belda1 Medical Oncology Service, La Paz Hospital, Pº de la Castellana, 261-28046, Madrid, Spain Tel.: +3 491 727 7118; Fax: +3 491 727 7118; E-mail: [email protected]
,
A Sundlov1 Medical Oncology Service, La Paz Hospital, Pº de la Castellana, 261-28046, Madrid, Spain Tel.: +3 491 727 7118; Fax: +3 491 727 7118; E-mail: [email protected]
,
E Casado1 Medical Oncology Service, La Paz Hospital, Pº de la Castellana, 261-28046, Madrid, Spain Tel.: +3 491 727 7118; Fax: +3 491 727 7118; E-mail: [email protected]
&
M González-Barón1 Medical Oncology Service, La Paz Hospital, Pº de la Castellana, 261-28046, Madrid, Spain Tel.: +3 491 727 7118; Fax: +3 491 727 7118; E-mail: [email protected]
Pages 931-942 | Published online: 14 Dec 2006

Bibliography

  • Boyle P , FerlayJ: Cancer incidence and mortality in Europe 2004.Ann. Oncol.16, 481–488(2005).
  • Gatta G , FaivreJ, CapocacciaR et al.: Survival of colorectal cancer patients in Europe during the period 1978–1989. EUROCARE Working Group. Eur. J. Cancer34, 2176–2183(1998).
  • Gatta G , SantM, CoeberghJW, Hakulinen T: Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987. Eur. J. Cancer32, 831–835(1996).
  • Schrag D , CramerLD, BachPB, BeggCB: Age and adjuvant chemotherapy use after surgery for stage III colon cancer.J. Natl Cancer Inst.93, 850–857(2001).
  • Sundararajan V , GrannV, NeugutA: Population based variation in the use of chemotherapy for colorectal cancer in the elderly.Proc. Am. Soc. Clin. Oncol.18, 413 (1999) (Abstract 1598).
  • Yee KW , PaterJL, PhoL et al.: Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J. Clin. Oncol.21, 1618–1623(2003).
  • De Marco MF , HeijnenML, van der HeijnenLH, CoeberghJW: Comorbidity and colorectal cancer according to subsite stage: a population-based study.Eur. J. Cancer36, 95–99(2000).
  • Rao AV , SeoPH, CohenHJ: Geriatric assaessment and comorbility.Semin. Oncol.31, 149–159(2004).
  • Carreca I , BalducciL, ExtremanM: Cancer in the older person.Cancer Treat. Rev.31, 380–402(2005).
  • Hamerman D : Toward an understanding of frailty.Ann. Intern. Med.130, 945–950(1999).
  • Extreman M , OvercashJ, LymanGH et al.: Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol.16, 1582–1587(1998).
  • Gosney MA : Clinical assessment of elderly people with cancer.Lancet Oncol.6, 790–797(2005).
  • Extermann M , AaproM, BernabeiR et al.: Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology. Crit. Rev. Oncol. Hematol.55, 241–252(2005).
  • Balducci L , ExtremanM: Management of cancer in the older person: a practical approach.Oncologist5, 224–237(2000).
  • Cohen HJ , FeussnerJR, WeinbergerM et al.: A cotrolled trial of inpatient and outpatient geriatric evaluation and management. N. Engl. J. Med.346, 905–912(2002).
  • Kuo HK , ScandrettKG, DaceJ et al.: The influence of outpatient geriatric assessment on survival. A meta-analysis. Arch. Gerontol. Ger.39, 245–254(2004).
  • Fried LP , TangenCM, WaltsonJ et al.: Frailty in older adults: evidence for a phenotype. J. Gerontol. Med. Sci.56A, 146–156(2001).
  • Mitry E , BouvierAM, EsteveJ, FaivreJ: Improvement in colorectal cancer survival: a population-based study.Eur. J. Cancer41, 2297–2303(2005).
  • Kemeny MM : Surgery in older patients.Sem. Oncol.31, 175–184(2004).
  • Lewis A , KhouryG: Resection for colorectal cancer in the very old: are the risk too high?BMJ296, 459–461(1988).
  • Whittle J , SteinbergE, AndersonG et al.: Results of colectomy in elderly patients with colon cancer, based on Medicare claims data. Am. J. Surg.163, 572–576(1992).
  • Colorectal Cancer Collaborative Group: Surgery for colorectal cancer in elderly patients: a systematic review. Lancet356, 968–974(2000).
  • Greenburg AG , SaikRP, ProdhamD: Influence of age on mortality of colon surgery.Am. J. Surg.150, 65–70(1985).
  • Spivak H , MaeleDV, FriedmanI et al.: Colorectal surgery in octogenarians. J. Am. Coll. Surg.183, 45–60(1996).
  • Keymling M : Colorectal stenting.Endocopy35, 234–238(2003).
  • Audisio RA , RameshH, LongoWH et al.: Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist10, 262–268(2005).
  • Temple LK , HsiehL, WongWD et al.: Use of surgery among elderly patients with stage IV colorectal cancer. J. Clin. Oncol.22, 3475–3484(2004).
  • Fong Y , BlumgartLH, FortnerJG et al.: Liver resection for colorectal metastases. J. Clin. Oncol.15, 938–846(1997).
  • Berber E , SipersteinAE: Predictors of survival after radiofrequency termal ablation of colorectal cancer metastases to the liver.J. Clin. Oncol.23, 1358–1364(2005).
  • Minsky BD , MiesC, RechtA et al.: Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer52, 1317–1329(1983).
  • Gastrintestinal Tumor Study Group: Prolongation of the disease free interval in surgically treated rectal carcinoma. N. Engl. J. Med.312, 1465–1472(1985).
  • Douglass HO Jr, Moertel CG, Mayer RJ et al.: Survival after postoperative combination treatment of rectal cancer. N. Engl. J. Med.315, 1294–1295(1986).
  • O´Connell MJ , MartensonJA, WieandHS et al.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5FU with radiation therapy after curative surgery. N. Engl. J. Med.331, 502–507(1994).
  • Sauer R , BeckerH, HohenbergerW et al.: German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med.351, 1731–1740(2004).
  • Martijn H , VoogdAC, van de Poll-Franse LV et al.: Improved survival of patients with rectal cancer since 1980: a population-based study. Eur. J. Cancer39, 2073–2079(2003).
  • Lewis JH , KilgoreML, GoldmanDP et al.: Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol.21, 1383–1389(2003).
  • Honecker F , KohneCH, BokemeyerC: Colorectal cancer in the elderly: is palliative chemotherapy of value?Drugs Aging20, 1–11(2003).
  • Lichtman SM : Chemotherapy in the elderly.Semin. Oncol.31, 160–174(2004).
  • Stein BN , PetrelliNJ, DougassHO et al.: Age and sex are independent factors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer75, 11–17(1995).
  • Popescu RA , NormanA, RossPJ et al.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol.17, 2412–2418(1999).
  • Köhne CH , CunninghamD, Di Costanzo F et al.: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients: Ann. Oncol.13, 308–317(2002).
  • Cassidy J , TwelvesC, Van Cutsem E et al.: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol.13, 566–575(2002).
  • Pazdur R , ZinnerR, RothenbergM et al.: Age as a risk factor in irinotecan (CPT-11) treatment of 5FU refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol.16, 260 (1997) (Abstract 921).
  • Rothenberg ML , CoxJV, De Vore FR et al.: A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcioma. Cancer85, 786–795(1999).
  • Rougier P , MitryE, CunninghamD et al.: Is age a prognostic factor of toxicity and efficacy in patients with metastatic colorectal cancer receiving irinotecan in combination with 5FU/folinic acid (FA). Proc. Am. Soc. Clin. Oncol.21, 267 (2003) (Abstract 1072).
  • Saltz L , CoxJ, BlankeC et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343, 905–914(2000).
  • De Gramont A , FigerA, SeymourM et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18, 2938–2947(2000).
  • Baretta M , BuonadonnaM, RupoloS et al.: Comparison between elderly and non- elderly patients (pts), of efficacy and tolerability of FOLFOX2 schedule in advanced coorectal cancer (COL). Proc. Am. Soc. Clin. Oncol.19, 111 (2001) (Abstract 2195).
  • Skillings JR , JohnsonDH, MillerK et al.: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc. Am. Soc. Clin. Oncol.23, 196 (2005) (Abstract 3019).
  • NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA264, 1444–1450(1990).
  • Sundarajan V , GrannVR, JacobsonJS et al.: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J.7, 213–218(2001).
  • Potosky AL , HarlanLC, KaplanRS et al.: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J. Clin. Oncol.20, 1192–1202(2002).
  • Jessup JM Stewart A, Greene FL, Minsky BD: Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA294, 2758–2760(2005).
  • Burdette-Radoux S , MussHB: Adjuvant chemotherapy in the elderly: whom to treat, what regimen.Oncologist11, 234–242(2006).
  • Moertel CG , FlemingTR, MacDonaldJS et al.: Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N. Engl. J. Med.322, 352–358(1990).
  • Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet345, 939–944(1995).
  • André T , BoniC, Mounedji-BoudiafL et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350, 2343–2351(2004).
  • Wolmark N , WieandHS, KueblerJP et al.: A Phase III trial comparing 5FULV to FULV + Oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol 07. Proc. Am. Soc. Clin. Oncol.23, 1902 (2005) (Abstract 3500).
  • Sargent DJ , GoldbergRM, JacobsonSD, MacdonaldJS: A pooled analysis of adjuvant chemotherapy for resected colon cancer in the elderly.N. Engl. J. Med.345, 1091–1097(2001).
  • Sundararajan V , MitraN, JacobsonJS et al.: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann. Intern. Med.136, 349–357(2002).
  • Au HJ , MuldrKE, FieldsAL: Systematic review of management of colorectal cancer in elderly patients.Clin. Colorectal Cancer3, 165–171(2003).
  • Twelves C , WongA, NowackiMP et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352, 2696–2704(2005).
  • Goldberg RM , Tabah-FischI, BleibergH et al.: Pooled analysis of safety and efficacy analysis of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol.24, 4085–4091(2006).
  • Vercelli M , CapocacciaR, QuagliaA et al.: Relative survival in elderly European cancer: evidence for health care inequalities. Crit. Rev. Oncol. Hematol.35, 161–179(2000).
  • Lembersky BC , WieandHS, Petrelli NJet al.: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol.24, 2059–2064(2006).
  • Twelves C , WongA, NowackiMP et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352, 2696–2704(2005).
  • Neugut AI , MatasarM, WangX et al.: Duration of adjuvant chemotherapy for colon cancer and survival among elderly. J. Clin. Oncol.24, 2368–2375(2006).
  • Venook A : Critical evaluation of current treatments in metastatic colorectal cancer.Oncologist10, 250–261(2005).
  • Folprecht G , RougierP, SaltzL et al.: Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan. Proc. Am. Soc. Clin. Oncol.24, 165 (2006) (Abstract 3578).
  • Extermann M , AlbrandG, ChenH et al.: Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol.21, 3214–3219(2003).
  • André T , BansmaineMA, LouvetC et al.: Multicenter Phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol.17, 3560–3568(1999).
  • Mosconi S , CascinuS, ZaniboniA et al.: The value of oxaliplatin in combination with continuous infusion ± bolus 5FU and levo-folinic acid in metastatic colorectal progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract). Tumori86, 465–469(2000).
  • Comella P , NataleD, FarrisA et al.: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer104, 282–289(2005).
  • Feliu J , SaludA, EscuderoP et al.: XELOX (Capecitabine plus Oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br. J. Cancer94, 969–975(2006).
  • Figer A , PerezN, CarolaE et al.: 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.22, 263 (2004) (Abstract 3571).
  • Mattioli R , MassacesiC, RecchiaF et al.: High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann. Oncol.16, 1147–1151(2005).
  • Sastre J , MarcuelloE, MassuttiB et al.: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J. Clin. Oncol.23, 3545–3551(2005).
  • Bollina R , BerettaG, TonioloD et al.: Capiri: a good combination regimen in first line elerly CRC patients. Proc. Am. Soc. Clin. Oncol.21, 332 (2003) (Abstract 1332).
  • Souglakos J , PallisA, KakolyrisD et al.: Combination of irinotecan (CPT-11) plus 5-Fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients wih metastatic colorectal cancer: a Phase II trial. Oncology69, 384–390(2005).
  • Fiorentini G , DenticoP, CantoreM et al.: Capecitabine (XE) plus irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer (MCRC) in elderly patients: feasibility and safety results from a Phase II study. Proc. Am. Soc. Clin. Oncol.23, 289 (2005) (Abstract 3676).
  • Rosati G , CordioS, TucciA et al.: Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology69, 122–129(2005).
  • Aparicio T , DesrameJ, LecomteT et al.: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br. J. Cancer89, 1439–1444(2003).
  • Tournigand C , CervantesA, FigerA et al.: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop- and- go fashion in advanced colorectal cancer – A GERCOR Study. J. Clin. Oncol.24, 394–400(2006).
  • Cassidy J , BjarnasonGA, HickishT et al.: Randomized double blind (DB) placebo (Plcb) controlled Phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol.26, 147 (2006) (Abstract 3507).
  • Cassidy J , TaberneroJ, TwelvesC et al.: XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol.22, 2084–2091(2004).
  • Comella P , FarrisA, LorussoV et al.: Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. Br. J. Cancer89, 992–996(2003).
  • Patt YZ , LinE, LeibmannJ et al.: Capecitabine (X) plus irinotecan (XELIRI) for first-line treatment for metstatic colorectal cancer (MCRC): final safety findings from a Phase II trial. Proc. Am. Soc. Clin. Oncol.21 (2003) (Abstract 1130).
  • Chau I , NormanAR, CunninghamD et al.: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br. J. Cancer91, 1453–1458(2004).
  • Feliu J , González-BarónM, EspinosaE et al.: Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer79, 1884–1889(1997).
  • Abad A : UFT plus folinic acid as therapy for metastatic colorectal cancer in older patients.Oncology11, 53–57(1999).
  • Popa EC , LuoH, HochsterH et al.: A Phase II study of orzel (UFT + leucovorin) in elderly (≥75 years old) patients with colorectal cancer: results of ECOG 1299. Proc. Am. Soc. Clin. Oncol.23, 273 (2005) (Abstract 3608).
  • Feliu J , MelJR, CampsC et al.: Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur. J. Cancer38, 1204–1211(2002).
  • Cripps MC , VincentM, JonkerD et al.: Dose reduced first-line capecitabine (XelodaTM) monotherapy in older and less fit patients with advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol.23, 265 (2005) (Abstract 3577).
  • Feliu J , EscuderoP, Llosa et al.: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An oncopaz Cooperative Group Study. J. Clin. Oncol.23, 3104–3111(2005).
  • Kabbinavar FF , SchultzJ, McCleodM et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol.23, 3697–3705(2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.